Low-fat diet reduces female pancreatic cancer risk

Share This Post

Investigative research suggests that diet may affect the risk of pancreatic cancer. The study investigated the effect of a low-fat diet on the incidence of pancreatic cancer.

The Women’s Healthy Diet Changes (WHI-DM) trial is a randomized controlled trial that included 48,835 postmenopausal women aged 50 to 79 years between 1993 and 1998. The enrolled women were randomly assigned to the intervention group (19,541 cases) with the goal of reducing their total fat intake and increasing the intake of vegetables, fruits, and grains; or the normal diet control group (29,294 cases). The intervention group was completed in March 2005. Through the application of log-rank test and multifactor Cox risk proportional model follow-up in 2014, the effect of dietary intervention on the incidence of pancreatic cancer was evaluated.

Intentional analysis included 46 200 women, 92 patients in the intervention group and 165 patients in the control group were diagnosed with pancreatic cancer (P = 0.23), multivariate analysis, the intervention group compared with the control group of pancreatic cancer risk ratio HR) is 0.86 (95% CI 0.67 ~ 1.11). For subjects with a baseline body mass index (BMI) of 25 kg / m2 or more, intervention can reduce the risk of pancreatic cancer (HR = 0.71, 95% CI 0.53 ~ 0.96). Intervention did not significantly reduce the risk of morbidity (HR = 1.62, 95% CI 0.97 ~ 2.71; P = 0.01). 

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy